ICLs effective over long-periods

Article

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

Kazutaka Kamiya, MD, PhD and colleagues from the University of Kitasato School of Medicine and Sanno Hospital, Tokyo, Japan conducted a study to determine the long-term clinical outcomes of implantation of a biocompatible collagen copolymer lens (Visian ICL, STAAR Surgical) in patients with high to moderate myopia. A total of 56 eyes (34 patients) with myopic refractive errors of -4 to -15.25 D received the lens and follow-up examinations were conducted 1, 3 and 6 months and 1, 2 and 4 years following surgery.

At four years postoperative, 79% of eyes were within ±0.5 D of target refraction and 93% were within ±1 D of target refraction. Mean manifest changes in refraction of -0.24 D occurred from 1 month to 4 years and no vision-threatening complications were observed.

The results of this study suggest that ICLs are safe and effective and can offer stable refractive results even over long time periods making them a suitable treatment option for eyes with moderate to high myopia.

Recent Videos
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.